A detailed history of Auxano Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, Auxano Advisors, LLC holds 2,502 shares of AMGN stock, worth $790,632. This represents 0.22% of its overall portfolio holdings.

Number of Shares
2,502
Previous 2,461 1.67%
Holding current value
$790,632
Previous $699,000 11.73%
% of portfolio
0.22%
Previous 0.21%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$262.75 - $319.31 $10,772 - $13,091
41 Added 1.67%
2,502 $781,000
Q1 2024

May 02, 2024

BUY
$268.87 - $324.56 $537 - $649
2 Added 0.08%
2,461 $699,000
Q4 2023

Feb 05, 2024

SELL
$255.7 - $288.46 $47,815 - $53,942
-187 Reduced 7.07%
2,459 $708,000
Q3 2023

Nov 07, 2023

BUY
$218.65 - $271.46 $18,147 - $22,531
83 Added 3.24%
2,646 $711,000
Q1 2023

Apr 27, 2023

BUY
$225.79 - $275.2 $12,870 - $15,686
57 Added 2.27%
2,563 $619,000
Q4 2022

Feb 03, 2023

BUY
$229.03 - $291.01 $2,061 - $2,619
9 Added 0.36%
2,506 $658,000
Q3 2022

Nov 02, 2022

BUY
$224.46 - $253.15 $5,611 - $6,328
25 Added 1.01%
2,497 $563,000
Q2 2022

Aug 05, 2022

SELL
$230.71 - $256.74 $1,153 - $1,283
-5 Reduced 0.2%
2,472 $601,000
Q1 2022

May 06, 2022

BUY
$219.27 - $242.57 $14,471 - $16,009
66 Added 2.74%
2,477 $599,000
Q4 2021

Feb 04, 2022

BUY
$198.88 - $227.6 $137,823 - $157,726
693 Added 40.34%
2,411 $542,000
Q2 2021

Aug 06, 2021

BUY
$233.58 - $259.14 $5,839 - $6,478
25 Added 1.48%
1,718 $419,000
Q1 2021

Apr 29, 2021

BUY
$221.91 - $258.6 $4,882 - $5,689
22 Added 1.32%
1,693 $421,000
Q4 2020

Feb 11, 2021

BUY
$216.38 - $257.67 $2,596 - $3,092
12 Added 0.72%
1,671 $384,000
Q2 2020

Aug 13, 2020

BUY
$197.81 - $242.74 $328,166 - $402,705
1,659 New
1,659 $391,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Auxano Advisors, LLC Portfolio

Follow Auxano Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Auxano Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Auxano Advisors, LLC with notifications on news.